EuroBiotech: More Articles of Note

The resignation of Peter Fellner has raised doubts about Ablynx’s united front against Novo Nordisk’s takeover bid. (NS Newsflash/CC BY 2.0)

> The resignation of Peter Fellner raised doubts about Ablynx’s united front against Novo Nordisk’s takeover bid. Fellner quit as chairman with immediate effect on the day Novo went public with its takeover attempt. Release

> Storm Therapeutics added £4 million ($5 million) to its series A round. The VC wing of Taiho Pharmaceutical put up the cash. Statement

> Galapagos and ProQR entered into a fibrosis research collaboration. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Cytovation raised an additional NOK 10 million ($1 million). The financing, which follows the raising of NOK 20 million, will support a phase 1/2a cutaneous warts trial. Statement

> Cypralis secured exclusive rights to certain macrocyclic inhibitors outside of oncology and virology. The inhibitors resulted from a research collaboration between Gilead and Selcia. Release

> Innate Pharma named Eric Vivier as its CSO. Statement

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.